No Detail Found!

Outcome of Haematopoietic Stem Cell Transplant in Beta-Thalassaemia Major: Single Centre Experience from a Low- and Middle-Income Country

Author(s)
Hashim Khan Department of Clinical Haematology, Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan
Tariq Ghafoor Department of Clinical Haematology, Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan
Nighat Shahbaz Department of Clinical Haematology, Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan
Tariq Azam Khattak Department of Clinical Haematology, Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan
Uzma Rahim Department of Clinical Haematology, Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan
Munazza Nabi Awan Department of Clinical Haematology, Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan
Abstract
To determine the outcome of haematopoietic stem transplant (HSCT) in beta-thalassaemia major (BTM) patients. Study Design: Descriptive Study. Place and Duration of the Study: Department of Clinical Haematology, Armed Forces Bone Marrow Transplant Centre (AFBMTC), Rawalpindi, Pakistan, from April 2018 to December 2023. Methodology: All cases of BTM undergoing HLA-matched allogeneic HSCT after myeloablative conditioning were included. Cases undergoing second HSCT and HSCT with treosulfan-based conditioning were excluded. Age, gender, complications, mortality, and associated factors were evaluated. Results: This study analysed the data of 118 cases of BTM including 71 (60.2%) males undergoing HSCT after myeloablative conditioning during the study period. The mean age at the time of HSCT was 85.7 ± 33.6 months. Eighty-one (68.6%) cases were in Pesaro Class III. Neutropenic fever was the most common complication documented in 117 (99.2%) cases. Mortality at day-100 was 14 (11.9%). Overall treatment-related mortality (TRM) was 23 (19.4%). In univariate analysis, factors having a statistically signi cant association with TRM were graft failure (p = 0.001), Pesaro class (p = 0.03), severity of acute graft versus host disease (aGVHD) (p = 0.02), and veno-occlusive disease (VOD) (p = 0.02). The median follow-up time was 26.87 ± 16.60 months with overall survival (OS) and disease free survival (DFS) rates of 80.5% and 78.0%, respectively. Conclusion: The OS of around 80% is promising which can be further improved with better transfusion services, regular iron chelation, and HSCT at a younger age.
Publication Details
Page(s) 513-518
Published Journal: Journal of the College of Physicians and Surgeons Pakistan, Volume: 35, Issue: 04, Year: 2025

Request the full text from PASTIC

Keywords
Pakistan, Beta-thalassaemia major, Haematopoietic stem cell transplant
References
Hamed EM,Meabed MH,Aly UF,Hussein RRS .2019 .Recent progress in gene therapy and other targeted therapeutic approaches for beta thalassaemia. Curr Drug Targets, 10(16) : 1603-23.
De Sanctis V,Kattamis C,Canatan D,Soliman AT,Elsedfy H,Karimi M .2017 .-Thalassaemia distribution in the old world: An ancient disease seen from a historical standpoint. Mediterr J Hematol Infect Dis, 018(1) : .
Ehsan H,Wahab A,Anwer F,Iftikhar R,Yousaf MN .2020 .Prevalence of transfusion transmissible infections in beta-thalassaemia major patients in pakistan: A systematic review. Cureus, 10(8) : .
Vitrano A,Calvaruso G,Lai E,Colletta G,Quota A,Gerardi C .2017 .The era of comparable life expectancy between thalassaemia major and intermedia: Is it time to revisit the major-intermedia dichotomy?. Br J Haematol, 10(1) : 124-30.
Mulas O,F O,Piroddi MG,Piras A,Vacca E,A E .2023 .Health-related quality-of-life pro le of pediatric patients with ²-thalassaemia after hematopoietic stem cell transplantation. J Clin Med, 10(18) : 6047.
Gaziev J,Isgro A,Sodani P,Marziali M,Paciaroni K,Gallucci C .2016 .Optimal outcomes in young class 3 patients with thalassaemia undergoing HLA-identical sibling bone marrow transplantation. Transplantation, 10(4) : 925-32.
Mathews V,George B,Deotare U,Lakshmi KM,Viswabandya A,Daniel D .2007 .A new strati cation strategy that identi es a subset of class III patients with an adverse prognosis among children with beta-thalassaemia major undergoing a matched related allogeneic stem cell transplantation. Biol Blood Marrow Transplant, 05(8) : 889-94.
Huang C,Qu Y,Liu S,Nie S,Jiang H .2021 .Hematopoietic stem cell transplantation for thalassaemia major using HLA fully matched and mismatched donor grafts. Transl Pediatr, 10(6) : 1552-65.
Hutt D.,Engraftment D.,Kenyon M,Babic A .2018 .The European blood and marrow transplantation textbook for nurses: Under the auspices of EBMT. Cham (CH. , 10 : 13-3.
Iftikhar R,Chaudhry QUN,Satti TM,Mahmood SK,Ghafoor T,Shamshad GU .2020 .Comparison of conventional cyclophosphamide versus udarabine-based conditioning in high-risk aplastic anemia patients undergoing matched-related donor transplantation. Clin Hematol Int, 200426(2) : 82-91.
Chaudhry HM,Bruce AJ,Wolf RC,Litzow MR,Hogan WJ,Patnaik MS .2015 .The incidence and severity of oral mucositis among allogeneic hematopoietic stem cell transplantation patients: A systematic review. Biol Blood Marrow Transplant, 09(4) : 605-16.
Dignan FL,Clark A,Amrolia P,Cornish J,Jackson G,Mahendra P .2012 .Diagnosis and management of acute graft-versus-host disease. Br J Haematol, 09129(1) : 2141-45.
Mohty M,Malard F,Alaskar AS,Aljurf M,Arat M,Bader P .2023 .Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: A re ned classi cation from the European society for blood and marrow transplantation (EBMT). Bone Marrow Transplant, 10(7) : 749-54.
Lucarelli G,Andreani M,Angelucci E. .2002 .The cure of thalassaemia by bone marrow transplantation. Blood Rev, 0192(2) : 81-5.
Bernardo ME,Piras E,Vacca A,Giorgiani G,Zecca M,Bertaina A .2012 .Allogeneic Hematopoietic stem cell transplantation in thalassaemia major: Results of a reduced-- toxicity conditioning regimen based on the use of treosulfan. -04- 423822., 10(2) : 473-6.
Choudhary D,Sharma SK,Gupta N,Kharya G,Pavecha P,Handoo A .2012 .Treosulfan-thiotepa- udarabine-based conditioning regimen for allogeneic transplantation in patients with thalassaemia major: A single-center experience from north India. Biol Blood Marrow Transplant, 11(3) : 492-5.
Mathews V,George B,Viswabandya A,Abraham A,Ahmed R,Ganapule A .2013 .Improved clinical outcomes of high risk ² thalassaemia major patients undergoing a HLA matched related allogeneic stem cell transplant with a treosulfan based conditioning regimen and peripheral blood stem cell grafts. PLoS One, 0061637(4) : .
Faulkner L,Uderzo C,Khalid S,Marwah P,Soni R,Yaqub N .2017 .ATG vs. thiotepa with busulfan and cyclophosphamide in matched-related bone marrow transplantation for thalassaemia. Blood Adv, 10(13) : 792-801.
Yesilipek MA,Uygun V,Kupesiz A,Karasu G,Ozturk G,Ertem M .2022 .Thalassaemia-free and graftv-ersus-host-free survival: Outcomes of Hematopoietic stem cell transplantation for thalassaemia major. Turkish experienceB.one Marrow Transplant, 10(5) : 760-7.
Sablo M,Chandy M,Wang Z,Logan BR,Ghavamzadeh A,Li CK .2011 .HLA-matched sibling bone marrow transplantation for ²-thalassaemia major. -09-306829., 10(5) : 1745-50.
Lai X,Liu L,Zhang Z,Shi L,Yang G,Wu M .2021 .Hepatic veno-occlusive disease/sinusoidal obstruction syndrome after hematopoietic stem cell transplantation for thalassaemia major: Incidence, management, and outcome. Bone Marrow Transplant, 10(7) : 1635-41.
Lucarelli G,Isgro A,Sodani P,Gaziev J .2012 .2(5):a011825. Cold Spring Harb Perspect Med, 10 : .
0

Citations

0

Downloads

91

Views